Abstract Number: 901 • 2019 ACR/ARP Annual Meeting
Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
Background/Purpose: Advanced imaging modalities such as ultrasound (US) and dual-energy CT (DECT) can help diagnose crystalline arthritis. DECT is a highly sensitive and specific modality…Abstract Number: 1178 • 2019 ACR/ARP Annual Meeting
Clinical Utility of DECT in the Diagnosis of Gout at Mayo Clinic in Florida
Background/Purpose: Gout is the most common inflammatory arthritis in the United States and worldwide. Precipitation of monosodium urate crystals in joints and soft tissues leads…Abstract Number: 1183 • 2019 ACR/ARP Annual Meeting
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Background/Purpose: More than 130 cases of gout of the spine have been reported, with presenting symptoms including acute back pain, neuropathy, and spinal compression; diagnosis…Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…Abstract Number: 1220 • 2019 ACR/ARP Annual Meeting
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Background/Purpose: Prevention of gout flares is a central concern to patients with gout. There are many potential ways that gout flares could be reported in…Abstract Number: 1226 • 2019 ACR/ARP Annual Meeting
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Background/Purpose: Neutrophils are key immune cells participating in host defense through several mechanisms, including the formation of neutrophil extracellular traps (NETs). Excessive neutrophil activation has…Abstract Number: 1227 • 2019 ACR/ARP Annual Meeting
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Background/Purpose: Patients with gout have an increased cardiovascular morbidity and mortality, not fully explained by traditional cardiovascular risk factors. Xanthine oxidase-induced oxidative stress, increased lipid…Abstract Number: 1228 • 2019 ACR/ARP Annual Meeting
Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout
Background/Purpose: Myeloid cells membrane-bound TREM-1 (mTREM-1) amplifies toll like receptor (TLR)-4-mediated myeloid cells activation, accompanied by release of soluble TREM-1 (sTREM-1) that acts as a…Abstract Number: 1230 • 2019 ACR/ARP Annual Meeting
Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics? Analysis of the UK Biobank
Background/Purpose: Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) associated with serum urate and gout. An association between diuretic use and gout has also…Abstract Number: 1231 • 2019 ACR/ARP Annual Meeting
Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Background/Purpose: Hyperuricemia is associated with non-alcoholic fatty liver disease (NAFLD) (Yang C et al. PlosOne2017; 12:e0177249; Jaruvongvanich V et al. Eur J Gastroenterol Hepatol 2017;…Abstract Number: 1232 • 2019 ACR/ARP Annual Meeting
Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation
Background/Purpose: The transcriptomic changes accompanying the transition from asymptomatic hyperuricemia to gout are currently unknown but may be important for identifying and understanding important molecular…Abstract Number: 1233 • 2019 ACR/ARP Annual Meeting
Identification and Characterization of a Novel Dysfunction Variant p.I242T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Background/Purpose: ABCG2 is a high-capacity urate transporter gene. Common dysfunctional variants of ABCG2 that result in decreased urate excretion in humans are major causes of…Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »